Pfizer (NYSE:PFE) filed an amendment Jan. 17 for its IPO that will sell 20% of its animal health business to the investing public. Expected to begin trading Feb. 1 on the New York Stock Exchange under the symbol ZTS, Zoetis will begin its new life as an independent company. Should you own its shares? I'll have a look.

Valuation
Pricing its shares between $22 and $25, Zoetis will have a market cap between $11 billion and $12.5 billion, making it a smallish large-cap or a large mid-cap, depending on your terminology. Either way, it's a decent-sized business. After doing a little back-of-the-napkin number crunching, I estimate its enterprise value will be $14.5 billion based on a mid-point share price of $23.50. Its estimated EBITDA based on no revenue growth in 2012 and a 16% operating margin is $833 million. Based on these assumptions, Zoetis' enterprise value when it goes public will be approximately 17.4 times EBITDA, 2.2 times higher than its parent.

SEE: Evaluating Pharmaceutical Companies

Competition
In terms of revenues, Zoetis is the largest business operating in the animal health medicines and vaccines industry. Its immediate peers include the animal health divisions of Merck & Co. (NYSE:MRK), Sanofi (NYSE:SNY), Eli Lilly and Company (NYSE:LLY) and others. With a commanding 19% market share, its competitiveness was a big reason Pfizer chose to spin off Zoetis rather than sell it to one of its human pharmaceutical competitors. Comparing Zoetis' valuation to its large-cap peers makes little sense. because most of them have significantly larger, mature human pharmaceutical businesses that are more conservatively valued, just like Pfizer.

The closest publicly traded comparison to Zoetis is U.K.-based Dechra Pharmaceuticals (OTCBB:DPHAF), which trades on the London Stock Exchange but is available over-the-counter in America. Dechra's revenues have grown 8.8% annually over the past four years to $660 million, while its operating income in the same four-year period has grown 17.7% to $56.7 million, an operating margin of 8.6%. On an EBITDA basis, its profit margin is 12%, 770 basis points less than Zoetis. Therefore, given that Dechra has an EBITDA margin 36% less than Zoetis, you could extrapolate that its enterprise value as a multiple of EBITDA would be similarly valued. On that basis, Dechra should have an enterprise value 11.1 times EBITDA, rather than its current 12.4 times. Either Dechra is overvalued or, more likely, Pfizer has slightly undervalued its animal health division.

SEE: Pharmaceutical Sector: Does The FDA Help Or Harm?

Should You Own?
Zoetis is a premiere player in the $100-billion animal health industry. Its main area of vaccines and medicines is a $22-billion market growing at 6% annually over the past five years. As I mentioned earlier, it is the global leader in animal vaccines and medicines with a billion-dollar gap in terms of annual revenue over Merck, its next biggest competitor. Operating in over 120 countries around the world, this is definitely an investment to consider if you're an animal owner.

A big difference between investing in Pfizer and Zoetis is the way in which the drugs are paid for. Most of Zoetis' revenues are self-pay in nature whereas most of Pfizer's involve some type of insurance or government agency. Pet owners paying out-of-pocket generally results in less pricing pressure, which translates into more consistent revenue and profitability. Zoetis' top 10 products account for just 38% of its revenue with no single brand able to bring down the company. Geographically, its revenues are spread globally with the U.S. accounting for 39% and emerging markets such as Brazil, China and India accounting for another 27%. Interestingly, the only region where it isn't No.1 is in Western Europe, a prime market for Dechra Pharmaceuticals. Now that Zoetis is independent, a company such as Dechra would seem to make an ideal acquisition.

SEE: The True Cost Of Pharmaceutical Scandals

The Bottom Line
Spin-offs often outperform the parent in the first 18 months following an initial public offering (IPO). Generally, the parent undervalues its subsidiary fearing investors won't pay top dollar to own the pure-play business. You can bet, however, that other major drug companies like Merck that compete with Pfizer's animal health business are watching this IPO closely. If it goes off without a hitch, which it should, you'll likely see similar IPOs in 2013 and beyond.

Zoetis expects to pay an annual dividend of 26 cents per share, providing investors with a 1% yield on its $25 share price. Its payout based on $595 million in net income in 2012 is 22%, suggesting it will have plenty of free cash flow to double its dividend in no time. I'm usually not a fan of IPOs, but I think this one's a winner. If you're a current Pfizer shareholder, you'll want to own some shares in Zoetis; if not, the same sentiment applies.

At the time of writing, Will Ashworth did not own any shares in any company mentioned in this article.

Related Articles
  1. Stock Analysis

    Analyzing Altria's Return on Equity (ROE) (MO)

    Learn about Altria Group's return on equity (ROE) and analyze net profit margin, asset turnover and financial leverage to determine what is causing its high ROE.
  2. Investing

    What Investors Need to Know About Returns in 2016

    Last year wasn’t a great one for investors seeking solid returns, so here are three things we believe all investors need to know about returns in 2016.
  3. Investing News

    Icahn's Bet on Cheniere Energy: Should You Follow?

    Investing legend Carl Icahn continues to lose money on Cheniere Energy, but he's increasing his stake. Should you follow his lead?
  4. Stock Analysis

    Analyzing Google's Return on Equity (ROE) (GOOGL)

    Learn about Alphabet's return on equity. How has its ROE changed over time, how does it compare to its peers and what factors are driving ROE for the company?
  5. Investing News

    Is Buffett's Bet on Oil Right for You? (XOM, PSX)

    Oil stocks are getting trounced, but Warren Buffett still likes one of them. Should you follow the leader?
  6. Stock Analysis

    The Top 5 Micro Cap Biotechnology Stocks for 2016 (BSTC, OSIR)

    Discover some of the most promising micro-cap biotechnology stocks that investors can consider for their 2016 investment portfolio.
  7. Investing News

    Chipotle Served with Criminal Probe

    Chipotle's beat muted expectations and got a clear bill from the CDC, but it now appears that an investigation into its E.coli breakout has expanded.
  8. Stock Analysis

    Analyzing Sprint Corp's Return on Equity (ROE) (S)

    Learn about Sprint's return on equity. Find out why its ROE is negative and how asset turnover and financial leverage impact ROE relative to Sprint's peers.
  9. Stock Analysis

    Why Alphabet is the Best of the 'FANGs' for 2016

    Alphabet just impressed the street, but is it the best FANG stock?
  10. Investing News

    A 2016 Outlook: What January 2009 Can Teach Us

    January 2009 and January 2016 were similar from an investment standpoint, but from a forward-looking perspective, they were very different.
RELATED FAQS
  1. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  2. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  3. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  4. How does additional paid in capital affect retained earnings?

    Both additional paid-in capital and retained earnings are entries under the shareholders' equity section of a company's balance ... Read Full Answer >>
  5. What types of capital are not considered share capital?

    The money a business uses to fund operations or growth is called capital, and there are a number of capital sources available. ... Read Full Answer >>
  6. What is the difference between issued share capital and subscribed share capital?

    The difference between subscribed share capital and issued share capital is the former relates to the amount of stock for ... Read Full Answer >>
COMPANIES IN THIS ARTICLE
Trading Center